Premium
Tau is not normally degraded by the proteasome
Author(s) -
Feuillette Sébastien,
Blard Olivier,
Lecourtois Magalie,
Frébourg Thierry,
Campion Dominique,
Dumanchin Cécile
Publication year - 2005
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.20414
Subject(s) - lactacystin , proteasome , ubiquitin , mg132 , endogeny , in vivo , proteasome inhibitor , frontotemporal dementia , neurodegeneration , microbiology and biotechnology , in vitro , tauopathy , biology , tau protein , alzheimer's disease , chemistry , biochemistry , disease , dementia , medicine , genetics , gene
Abstract Tau‐positive inclusions in neurons are consistent neuropathologic features of the most common causes of dementias such Alzheimer's disease and frontotemporal dementia. Ubiquitinated tau‐positive inclusions have been reported in brains of Alzheimer's disease patients, but involvement of the ubiquitin‐dependent proteasomal system in tau degradation remains controversial. Before considering the tau degradation in pathologic conditions, it is important to determine whether or not endogenous tau is normally degraded by the proteasome pathway. We therefore investigated this question using two complementary approaches in vitro and in vivo. Firstly, SH‐SY5Y human neuroblastoma cells were treated with different proteasome inhibitors, MG132, lactacystin, and epoxomicin. Under these conditions, neither total nor phosphorylated endogenous tau protein levels were increased. Instead, an unexpected decrease of tau protein was observed. Secondly, we took advantage of a temperature‐sensitive mutant allele of the 20S proteasome in Drosophila . Genetic inactivation of the proteasome also resulted in a decrease of tau levels in Drosophila . These results obtained in vitro and in vivo demonstrate that endogenous tau is not normally degraded by the proteasome. © 2005 Wiley‐Liss, Inc.